Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus STAVUDINE LAMIVUDINE EFAVIRENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus STAVUDINE LAMIVUDINE EFAVIRENZ.
EMTRICITABINE vs STAVUDINE; LAMIVUDINE; EFAVIRENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Combination antiretroviral: stavudine is a nucleoside reverse transcriptase inhibitor (NRTI); lamivudine is an NRTI; efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Stavudine and lamivudine are phosphorylated intracellularly to active triphosphate metabolites that compete with natural substrates and incorporate into viral DNA, causing chain termination. Efavirenz binds directly to reverse transcriptase, causing allosteric inhibition and preventing RNA-dependent DNA polymerization.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet (stavudine 30 mg + lamivudine 150 mg + efavirenz 600 mg) orally once daily on an empty stomach, preferably at bedtime.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Stavudine: 1.0-1.6 h (adults), 2.5-5.0 h (neonates). Lamivudine: 5-7 h (adults), 10-14 h (neonates). Efavirenz: 40-55 h (single dose), 52-76 h (multiple doses).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Stavudine: 40% renal (unchanged), 60% biliary/fecal (metabolites). Lamivudine: 70% renal (unchanged), 30% fecal (metabolites). Efavirenz: 16-61% renal (metabolites), 14-34% fecal (unchanged).
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."